search
Back to results

Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment (EXcellenT)

Primary Purpose

Non-Small Cell Lung Cancer

Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Supervised physical activity
Unsupervised physical activity
Sponsored by
AUSL Romagna Rimini
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Non-Small Cell Lung Cancer focused on measuring NSCLC, Oncogene addiction, physical activity, personalized

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age 18 years or older
  2. Willingness to provide written informed consent.
  3. Life expectancy >12 weeks.
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  5. Body massa index > 18.
  6. Oncogene-addicted (EGFR, ALK, ROS1, RET, BRAF) stage IV or III b not suitable for local treatment receiving first- or second-line systemic treatment (palliative radiotherapy and prior chemotherapy allowed). Patients undergoing treatment in clinical trials are excluded.

Exclusion Criteria:

  1. Inability to walk.
  2. Immobility for more than 3 days before study enrollment.
  3. Previously untreated (non-irradiated or non-resected) symptomatic brain metastases.
  4. Severe cardiac impairment (e.g. cardiac insufficiency New York Heart Association (NYHA) > III, myocardial infarction within the last three months, severe cardiac arrhythmias, high grade aortic stenosis).
  5. Severe respiratory failure.
  6. Uncontrolled pain.
  7. Bone metastasis inducing increased risk of pathological fractures.

Sites / Locations

  • S.Maria delle Croci Hospital, Oncology UnitRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

A - Home based supervised physical exercise

B- Unsupervised physical exercise

Arm Description

patients will have a home-based physical activity prescription

patients will receive a physical activity counselling, without a real prescription and supervision

Outcomes

Primary Outcome Measures

Impact of personalized prescription of physical exercises on quality of life assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30)
To evaluate the impact of a personalized prescription of physical exercises monitored through a special smartphone application on quality of life assessed with the Italian version of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30)
Impact of personalized prescription of physical exercises on quality of life assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire for lung cancer (QLQ-LC29)
To evaluate the impact of a personalized prescription of physical exercises monitored through a special smartphone application on quality of life assessed with the Italian version of the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire for lung cancer (QLQ-LC29)
Impact of personalized prescription of physical exercises on quality of life assessed by the Beck Depression Inventory II (BDI-II)
To evaluate the impact of a personalized prescription of physical exercises monitored through a special smartphone application on quality of life assessed with the Italian version of Beck Depression Inventory II (BDI-II)

Secondary Outcome Measures

Adherence to prescription
To evaluate the adherence to the step-counter and the strength training prescription monitored through a specific smartphone application. the number of weeks (at least 9 out of 12 weeks) a subject follows the personalized activity prescription will be measured
change of functional capacity
Functional capacity will be measured through the 1 Km treadmill test (at baseline; at week 4, week 8 and at week 12): arm A versus arm B. For those in the experimental arm, as the individual progresses with the exercise plan, the exercise dosage will be modulated to facilitate improvements.
change of muscle strength
Muscle strength will be measured through the maximum repetition tests (at baseline; at week 4, week 8 and at week 12): arm A versus arm B. For those in the experimental arm, as the individual progresses with the exercise plan, the exercise dosage will be modulated to facilitate improvements.
tolerance to treatment
Monitoring the frequency, duration, and severity of adverse events (AEs), through physical examinations, changes in vital signs and through clinical laboratory blood.
Overall survival (OS)
Overall survival (OS), defined as the time from randomization to death from any cause.
Patient's satisfaction assessed by dedicated questionnaire
Patient's satisfaction of an App-based system to guide and monitor home-based physical activity is assessed by dedicated questionnaire addressing specific issues
impact of personalized exercise on immunity state
T Lymphocytes modulation during physical activity

Full Information

First Posted
February 22, 2022
Last Updated
May 29, 2023
Sponsor
AUSL Romagna Rimini
Collaborators
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
search

1. Study Identification

Unique Protocol Identification Number
NCT05306652
Brief Title
Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment
Acronym
EXcellenT
Official Title
Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 4, 2022 (Actual)
Primary Completion Date
June 1, 2024 (Anticipated)
Study Completion Date
June 1, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AUSL Romagna Rimini
Collaborators
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is an interventional, non-pharmacologic, randomized controlled study evaluating the impact on quality of life of a personalized exercise program in oncogene addicted lung cancer patients undergoing active treatment. Patients will be randomized 1:1 in two arms: arm A (interventional) and arm B (control). The program of physical activity will be established after a test done at the local clinical center and based on easy exercises already studied in other diseases (e.g. coronary syndrome or organ transplant). A smartphone application will allow patients to register their daily physical activity and to easily recover data on strength and endurance. Patients in Arm A will have a home-based physical activity prescription and will be supervised at weeks: 4, 6, 8, 10, 12 by the oncologist and an exercise expert of the local sport center through three exercises (body composition test, endurance test and strength test) and questionnaires. Home-based activity will be monitored daily though a specific application (provided by Technogym). Patients in Arm B will receive an exercise counselling without a subsequent supervision. The three tests and questionnaires will be repeated once a month for three months at the local sport center and oncology center. Counselling will include general information on exercise. Patients will undergo blood sampling at baseline, week 4 and week 12 in order to evaluate changes in their immunological state (lymphocyte populations and cytokines).
Detailed Description
This is an interventional, non pharmacological, randomized controlled trial evaluating the impact on quality of life of a personalized exercise program in oncogene addicted lung cancer patients undergoing active treatment. At Baseline every patient will receive three tests at the Division of Sport Medicine of Azienda Unità Sanitaria Locale (AUSL) of Romagna (Ravenna) Body composition Analysis: Height, Weight, Bioimpedentiometry (resistance and reactance), Volume of Oxygen (VO2) max. Endurance test: 1 Km treadmill test. Strength test: Repetition of three different exercises (Chest press - upper limbs; Leg press - lower limbs; Lat pull down or Lat Machine or Upper Back). After the three tests have been performed patients will be evaluated for eligibility and randomized into two arms: Arm A (interventional) and Arm B (control). The program will be guided (prescribed and supervised) by an oncologist and a sport medicine doctor. Arm A (interventional): patients will have a home-based physical activity prescription, defined on the functional endurance and strength tests and they will be supervised for 3 months. Once monthly they will be examined by the oncologist (visit and questionnaires) and at weeks 4, 6, 8, 10 and 12 at the sport medicine center where the three tests will be repeated. Home-based activity will be monitored daily through a specific application (provided by Technogym). Endurance improvement is defined as an increase in walking speed; strength improvement is defined as an increase of the number of repetitions. Arm B (control): patients will receive a physical activity counselling, without a real prescription and supervision, and the three test will be repeated once a month for three months at the local sport medicine center and at the oncology center (visit and questionnaires). Counselling will include general informations on physical exercise.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-Small Cell Lung Cancer
Keywords
NSCLC, Oncogene addiction, physical activity, personalized

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
A - Home based supervised physical exercise
Arm Type
Experimental
Arm Description
patients will have a home-based physical activity prescription
Arm Title
B- Unsupervised physical exercise
Arm Type
Active Comparator
Arm Description
patients will receive a physical activity counselling, without a real prescription and supervision
Intervention Type
Other
Intervention Name(s)
Supervised physical activity
Intervention Description
patients will have a home-based physical activity prescription, defined on the functional endurance and strength tests and they will be supervised for 3 months. Once monthly they will be examined by the oncologist (visit and questionnaires) and at weeks 4, 6, 8, 10 and 12 at the sport medicine center where the three tests will be repeated. Home-based activity will be monitored daily through a specific application. Endurance improvement is defined as an increase in walking speed; strength improvement is defined as an increase of the number of repetitions
Intervention Type
Other
Intervention Name(s)
Unsupervised physical activity
Intervention Description
patients will receive a physical activity counselling, without a real prescription and supervision, and the three test will be repeated once a month for three months at the local sport medicine center and at the oncology center (visit and questionnaires). Counselling will include general informations on physical exercise
Primary Outcome Measure Information:
Title
Impact of personalized prescription of physical exercises on quality of life assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30)
Description
To evaluate the impact of a personalized prescription of physical exercises monitored through a special smartphone application on quality of life assessed with the Italian version of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30)
Time Frame
12 weeks
Title
Impact of personalized prescription of physical exercises on quality of life assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire for lung cancer (QLQ-LC29)
Description
To evaluate the impact of a personalized prescription of physical exercises monitored through a special smartphone application on quality of life assessed with the Italian version of the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire for lung cancer (QLQ-LC29)
Time Frame
12 weeks
Title
Impact of personalized prescription of physical exercises on quality of life assessed by the Beck Depression Inventory II (BDI-II)
Description
To evaluate the impact of a personalized prescription of physical exercises monitored through a special smartphone application on quality of life assessed with the Italian version of Beck Depression Inventory II (BDI-II)
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Adherence to prescription
Description
To evaluate the adherence to the step-counter and the strength training prescription monitored through a specific smartphone application. the number of weeks (at least 9 out of 12 weeks) a subject follows the personalized activity prescription will be measured
Time Frame
12 weeks
Title
change of functional capacity
Description
Functional capacity will be measured through the 1 Km treadmill test (at baseline; at week 4, week 8 and at week 12): arm A versus arm B. For those in the experimental arm, as the individual progresses with the exercise plan, the exercise dosage will be modulated to facilitate improvements.
Time Frame
12 weeks
Title
change of muscle strength
Description
Muscle strength will be measured through the maximum repetition tests (at baseline; at week 4, week 8 and at week 12): arm A versus arm B. For those in the experimental arm, as the individual progresses with the exercise plan, the exercise dosage will be modulated to facilitate improvements.
Time Frame
12 weeks
Title
tolerance to treatment
Description
Monitoring the frequency, duration, and severity of adverse events (AEs), through physical examinations, changes in vital signs and through clinical laboratory blood.
Time Frame
12 weeks
Title
Overall survival (OS)
Description
Overall survival (OS), defined as the time from randomization to death from any cause.
Time Frame
24 months
Title
Patient's satisfaction assessed by dedicated questionnaire
Description
Patient's satisfaction of an App-based system to guide and monitor home-based physical activity is assessed by dedicated questionnaire addressing specific issues
Time Frame
12 weeks
Title
impact of personalized exercise on immunity state
Description
T Lymphocytes modulation during physical activity
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 years or older Willingness to provide written informed consent. Life expectancy >12 weeks. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Body massa index > 18. Oncogene-addicted (EGFR, ALK, ROS1, RET, BRAF) stage IV or III b not suitable for local treatment receiving first- or second-line systemic treatment (palliative radiotherapy and prior chemotherapy allowed). Patients undergoing treatment in clinical trials are excluded. Exclusion Criteria: Inability to walk. Immobility for more than 3 days before study enrollment. Previously untreated (non-irradiated or non-resected) symptomatic brain metastases. Severe cardiac impairment (e.g. cardiac insufficiency New York Heart Association (NYHA) > III, myocardial infarction within the last three months, severe cardiac arrhythmias, high grade aortic stenosis). Severe respiratory failure. Uncontrolled pain. Bone metastasis inducing increased risk of pathological fractures.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Chiara Bennati, MD
Phone
+39 0544 285778
Email
chiara.bennati@auslromagna.it
First Name & Middle Initial & Last Name or Official Title & Degree
Michela Spreafico
Email
michela.spreafico@irst.emr.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chiara Bennati
Organizational Affiliation
AUSL Romagna
Official's Role
Principal Investigator
Facility Information:
Facility Name
S.Maria delle Croci Hospital, Oncology Unit
City
Ravenna
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chiara Bennati, MD
Email
chiara.bennati@auslromagna.it

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment

We'll reach out to this number within 24 hrs